ClinicalTrials.gg
CompletedNCT05673993Updated Oct 1, 2025

A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

A Phase 3 interventional study of Telitacicept 80 mg and Telitacicept 160 mg in Primary Sjogren's Syndrome, sponsored by RemeGen Co., Ltd.. Completed at 78 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by RemeGen Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
381
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Sjogren's Syndrome with a site in China — 28 open to participants now, 32 under way, 5 of them phase 3. Sjogren's Syndrome · China.

Enrollment
6th of 47
381 · median 30
Started
2023
with 5 others
Phase 3
7 of 55
1 open now
Registered
18th of 55
by date

Among the 55 studies in Sjogren's Syndrome with a site in China, this one is the 6th largest by enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2023, is one of 7 in phase 3, and was the 18th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

28 of the 55 studies in Sjogren's Syndrome with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Sjogren's Syndrome with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of subcutaneous Telitacicept versus placebo in subjects with active primary Sjogren's Syndrome.

Read the detailed description

This is a phase Ⅲ, multi-center, randomized, double-blind, placebo-controlled study. Subjects with active primary Sjogren's Syndrome (pSS) will be randomized to receive subcutaneous Telitacicept 80 mg, Telitacicept 160 mg or placebo weekly for a total of 48 weeks. Subjects are allowed to be transferred to another group after Week 24 by the investigator so that those randomized to the placebo group are able to receive either Telitacicept 80 mg or Telitacicept 160 mg afterwards. Subjects who are randomized to Telitacicept 80 mg and Telitacicept 160 mg groups will remain in the previous treatment group even if the investigator chooses to transfer them. Subjects and investigators are blinded throughout the study.

03

Conditions studied

  • Primary Sjogren's Syndrome

Browse trials for

Keywords

  • primary Sjogren's Syndrome
  • pSS
  • RC18
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Written provided.
  2. Males and females, 18-70 years of age.
  3. Fulfilled the classification criteria of pSS according to ACR/EULAR (2016).
  4. Anti-SSA antibody tested positive at screening.
  5. ESSDAI score ≥ 5 at screening.

Main Exclusion Criteria:

  1. Secondary Sjogren's syndrome.
  2. Severe organ involvement related to pSS in the opinion of the investigator, including but not limited to a) severe vasculitis (not cutaneous vasculitis) affecting the kidney, gastrointestinal system, cardiac, pulmonary or central nervous system (CNS); b) active CNS or peripheral nervous system involvement requiring high dose ; c) severe kidney involvement, e.g. \< 60 ml/min, serum creatinine > 2 mg/dL, or proteinuria > 3g/d; d) severe pulmonary involvement, e.g. shortness of breath at rest, FVC \< 60% or DLCO \< 40%; e) muscle diseases requiring high dose corticosteroids; f) lymphoma.
  3. Received sodium hyaluronate eye drops, artificial tears or artificial saliva within 7 days prior to screening.
  4. Received within 28 days prior to randomization.
  5. Active hepatitis or history of severe liver diseases.
  6. positive.
  7. Patients with malignant tumors.
  8. Received pharmaceutical within 28 days or 5 half-lives prior to randomization, whichever is longer.
  9. Nursing or pregnant female, or male or female who prepared for parenthood during the study.
  10. Any condition that, in the opinion of the investigator, makes it unsuitable for the subject to participate, e.g., poorly controlled high blood pressure, diabetes, heart failure or mental illness.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
381 participants (actual)

Study arms

  • Experimental
    Telitacicept 80 mg

    Subjects will be given subcutaneous Telitacicept 80 mg once a week for 48 weeks.

    Biological: Telitacicept 80 mg

  • Experimental
    Telitacicept 160 mg

    Subjects will be given subcutaneous Telitacicept 160 mg once a week for 48 weeks.

    Biological: Telitacicept 160 mg

  • Placebo comparator
    Placebo

    Subjects will be given subcutaneous placebo once a week for 24-48 weeks. Subjects who are randomized to the placebo group are allowed to be transferred to either Telitacicept 80 mg or Telitacicept 160 mg after Week 24 by the investigator. Subjects and investigators are blinded throughout the study.

    Drug: Placebo

Interventions

  • Telitacicept 80 mg subcutaneously once a week.

    Also known as: RC 18 80 mg

  • Telitacicept 160 mg subcutaneously once a week.

    Also known as: RC 18 160 mg

  • DrugPlacebo

    Subjects will be given subcutaneous placebo once a week.

06

What researchers measure

Primary outcomes

  1. Change from baseline in ESSDAI score

    The EULAR Sjogren's syndrome (SS) disease activity index (ESSDAI) is a systemic disease activity index that was designed to measure disease activity in patients with primary SS. It includes 12 domains (ie, organ systems: cutaneous, respiratory, renal, articular, muscular, peripheral nervous system (PNS), central nervous system (CNS), haematological, glandular, constitutional, lymphadenopathic, biological). Each domain is divided into 3-4 levels of activity (no, low, moderate, high). Overall score is calculated as sum of all individual weighted domain scores (ranges from 0 (best) to 123 (worst activity). A higher score indicates worsening of the disease.

    Time frame: Week 24

Secondary outcomes

  1. Change from baseline in ESSDAI score

    The EULAR Sjogren's syndrome (SS) disease activity index (ESSDAI) is a systemic disease activity index that was designed to measure disease activity in patients with primary SS. It includes 12 domains (ie, organ systems: cutaneous, respiratory, renal, articular, muscular, peripheral nervous system (PNS), central nervous system (CNS), haematological, glandular, constitutional, lymphadenopathic, biological). Each domain is divided into 3-4 levels of activity (no, low, moderate, high). Overall score is calculated as sum of all individual weighted domain scores (ranges from 0 (best) to 123 (worst activity). A higher score indicates worsening of the disease.

    Time frame: Week 48

  2. Percentage of subjects with ESSDAI score decreased from baseline by at least 3 points

    The EULAR Sjogren's syndrome (SS) disease activity index (ESSDAI) is a systemic disease activity index that was designed to measure disease activity in patients with primary SS. It includes 12 domains (ie, organ systems: cutaneous, respiratory, renal, articular, muscular, peripheral nervous system (PNS), central nervous system (CNS), haematological, glandular, constitutional, lymphadenopathic, biological). Each domain is divided into 3-4 levels of activity (no, low, moderate, high). Overall score is calculated as sum of all individual weighted domain scores (ranges from 0 (best) to 123 (worst activity). A higher score indicates worsening of the disease

    Time frame: Week 24 & Week 48

  3. Percentage of subjects with ESSDAI score < 5

    The EULAR Sjogren's syndrome (SS) disease activity index (ESSDAI) is a systemic disease activity index that was designed to measure disease activity in patients with primary SS. It includes 12 domains (ie, organ systems: cutaneous, respiratory, renal, articular, muscular, peripheral nervous system (PNS), central nervous system (CNS), haematological, glandular, constitutional, lymphadenopathic, biological). Each domain is divided into 3-4 levels of activity (no, low, moderate, high). Overall score is calculated as sum of all individual weighted domain scores (ranges from 0 (best) to 123 (worst activity). A higher score indicates worsening of the disease.

    Time frame: Week 24 & Week 48

  4. Percentage of subjects with ESSPRI score decreased from baseline by at least 1 point or 15%

    The EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) is a patient-reported, subjective symptom index for primary Sjögren's syndrome. It consists of three questions covering the cardinal symptoms of Sjögren's syndrome: dryness, fatigue and pain (articular and/or muscular). Each domain scored on scale of 0-10 (0 =no symptom at all and 10 = worst symptom imaginable), and an overall score is calculated as the mean of the three individual domains.

    Time frame: Week 24 & Week 48

  5. Change from baseline in MFI-20

    The multidimensional fatigue inventory (MFI-20) is a 20-item self-report instrument designed to measure fatigue. It covers the following dimensions: general fatigue, physical fatigue, reduced activity, reduced motivation and mental fatigue. Each question is scored from one to five and each dimension consists of five questions. The dimensional score consequently ranges from 4 to 20 (a higher score indicates more fatigue).

    Time frame: Week 24 & Week 48

  6. Incidence of AEs, SAEs

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death; is life-threatening experience; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or is a congenital anomaly/ birth defect; or any other important medical event that may not be immediately life-threatening or result in death or hospitalization but may require intervention to prevent one of the other serious outcomes listed in the definition above.

    Time frame: Up to Week 48

07

Study locations

78 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui, China
  • Anhui Provincial Hospital
    Hefei, Anhui, China
  • Beijing Tongren Hospital, Capital Medical University
    Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality, China
  • Peking University Shougang Hospital
    Beijing, Beijing Municipality, China
  • Xuanwu Hospital of Capital Medical University
    Beijing, Beijing Municipality, China
  • The First Affiliated Hospital of Army Medical University
    Chongqing, Chongqing Municipality, China
  • The Second Affiliated Hospital of Fujian Medical University
    Quanzhou, Fujian, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
  • Sun Yat-sen Memorial Hospital
    Guangzhou, Guangdong, China
  • Zhujiang Hospital of Southern Medical University
    Guangzhou, Guangdong, China
  • Meizhou People's Hospital
    Meizhou, Guangdong, China
  • Shenzhen People's Hospital
    Shenzhen, Guangdong, China
  • South China Hospital of Shenzhen University
    Shenzhen, Guangdong, China
  • Zhongshan Hospital of Traditional Chinese Medicine
    Zhongshan, Guangdong, China
  • Guilin People's Hospital
    Guilin, Guangxi, China
  • The Second Affiliated Hospital of Guilin Medical University
    Guilin, Guangxi, China
  • Liuzhou Workers' Hospital
    Liuzhou, Guangxi, China
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi, China
  • The Affiliated Hospital of Guizhou Medical University
    Guiyang, Guizhou, China
  • The Affiliated Hospital of Zunyi Medical University
    Zunyi, Guizhou, China
  • Affiliated Hospital of Hebei University
    Baoding, Hebei, China
  • Hebei PetroChina Central Hospital
    Langfang, Hebei, China
  • The Second Affiliated Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • The First Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan, China
  • People's Hospital of Zhengzhou
    Zhengzhou, Henan, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • The First People's Hospital of Changde
    Changde, Hunan, China
  • Hunan Provincial People's Hospital
    Changsha, Hunan, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The First People's Hospital of Chenzhou
    Chenzhou, Hunan, China
  • The Second People's Hospital of Changzhou
    Changzhou, Jiangsu, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu, China
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu, China
  • First Affiliated Hospital of Gannan Medical University
    Ganzhou, Jiangxi, China
  • Ganzhou People's Hospital
    Ganzhou, Jiangxi, China
  • Jiangxi Provincial People's Hospital
    Nanchang, Jiangxi, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • Pingxiang People's Hospital
    Pingxiang, Jiangxi, China
  • Jilin Province People's Hospital
    Changchun, Jilin, China
  • Yanbian University Hospital (Yanbian Hospital)
    Yanji, Jilin, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning, China
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi, China
  • Binzhou Medical University Hospital
    Binzhou, Shandong, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
  • Shandong Provincial Hospital
    Jinan, Shandong, China
  • Jining No 1 People's Hospital
    Jining, Shandong, China
  • Yantai Yuhuangding Hospital
    Yantai, Shandong, China
  • Yantaishan Hospital
    Yantai, Shandong, China
  • Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality, China
  • Shanghai Ninth People's Hopital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality, China
  • Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi, China
  • Shanxi Provincial People's Hospital
    Taiyuan, Shanxi, China
  • West China Hospital Sichuan University
    Chengdu, Sichuan, China
  • Deyang People's Hospital
    Deyang, Sichuan, China
  • Mianyang Central Hospital
    Mianyang, Sichuan, China
  • Affiliated Hospital of North Sichuan Medical College
    Nanchong, Sichuan, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality, China
  • People's Hospital of Xinjiang Uygur Autonomous Region
    Ürümqi, Xinjiang, China
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
  • The First People's Hospital of Yunnan Province
    Kunming, Yunnan, China
  • Dongyang People's Hospital
    Dongyang, Zhejiang, China
  • The Second Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang, China
  • Huzhou Third Municipal Hospital
    Huzhou, Zhejiang, China
  • The First Hospital of Jiaxing
    Jiaxing, Zhejiang, China
  • The Second Hospital of Jiaxing
    Jiaxing, Zhejiang, China
  • Jinhua Municipal Central Hospital
    Jinhua, Zhejiang, China
  • Ningbo Medical Center (Lihuili Hospital)
    Ningbo, Zhejiang, China
  • The First People's Hospital of Wenling
    Wenling, Zhejiang, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
  • The People's Hospital of Wenzhou
    Wenzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Oct 2024, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2022
First posted
Jan 6, 2023
StartActual
Apr 6, 2023
Primary completionActual
Oct 29, 2024
CompletionActual
May 6, 2025
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05673993
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Jan 6, 2023
Start date
Apr 6, 2023
Primary completion
Oct 29, 2024
Completion
May 6, 2025
Last update
Oct 1, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telitacicept

Start the discussion